Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

2.0K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.0K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

7.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
7.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

2.8K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD38 defines a therapeutically targetable pathogenic T cell population for precision immunotherapy in autoimmune diabetes.

bioRxiv : the preprint server for biology·2026
Same author

Why and How to Monitor Deployed AI Systems in Health Care.

NEJM catalyst innovations in care delivery·2026
Same author

Gordon C. Weir, 3 December 1940-27 March 2026.

Diabetologia·2026
Same author

Co-intelligence: a proposal for human-artificial intelligence collaboration for large language models in medical research.

The Lancet. Digital health·2026
Same author

Artificial Intelligence in Peripheral Artery Disease: A Science Advisory From the American Heart Association.

Circulation. Population health and outcomes·2026
Same author

Physician-Reported Safety Outcomes of AI-Generated Hospital Course Summaries.

JAMA network open·2026

Related Experiment Video

Updated: Apr 26, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

10.4K

Repurposing cAMP-modulating medications to promote β-cell replication.

Zhenshan Zhao1, Yen S Low, Neali A Armstrong

  • 1Department of Medicine and Division of Endocrinology, Gerontology, and Metabolism (Z.Z., N.A.A., S.A.S., J.P.A.) and Stanford Center for Biomedical Informatics Research (Y.S.L.), Stanford University School of Medicine, Stanford, California 94306; Department of Stem Cell and Regenerative Biology (J.H.R., A.C.A.), Harvard University, Cambridge, Massachusetts 02138; and Section of Islet Cell and Regenerative Biology (J.H.-L., G.C.W.), Joslin Diabetes Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115.

Molecular Endocrinology (Baltimore, Md.)
|August 2, 2014
PubMed
Summary
This summary is machine-generated.

Certain medications can promote the regeneration of insulin-producing beta cells, crucial for diabetes treatment. Phosphodiesterase inhibitors like dipyridamole and mirtazapine stimulate beta cell growth by modulating cyclic AMP levels.

More Related Videos

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets
09:31

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets

Published on: June 25, 2012

13.4K
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

5.9K

Related Experiment Videos

Last Updated: Apr 26, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

10.4K
Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets
09:31

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets

Published on: June 25, 2012

13.4K
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

5.9K

Area of Science:

  • Endocrinology
  • Cell Biology
  • Pharmacology

Background:

  • Loss of beta-cell mass is a primary characteristic of diabetes.
  • Developing therapies for beta-cell regeneration is a critical research area.
  • Cyclic AMP (cAMP) is a key intracellular messenger regulating beta-cell replication.

Purpose of the Study:

  • To identify medications that enhance beta-cell growth by increasing cAMP stability or synthesis.
  • To investigate the role of phosphodiesterase (PDE) inhibitors and adrenergic signaling in beta-cell replication.

Main Methods:

  • High-content screening of a phosphodiesterase inhibitor library.
  • Assessing the effects of dipyridamole and mirtazapine on beta-cell replication in vitro and in vivo.
  • Investigating the mechanisms involving adenosine receptors, alpha(2)-adrenergic receptors, and catecholamine-inactivating enzymes.

Main Results:

  • PDE3, -4, and -10 inhibitors, including dipyridamole, promoted beta-cell replication via adenosine receptors, specifically in beta-cells.
  • Norepinephrine (NE) suppresses beta-cell replication by activating alpha(2)-adrenergic receptors, an effect dominant over PDE inhibitors.
  • Mirtazapine, an alpha(2)-adrenergic receptor antagonist, prevented NE-induced suppression of beta-cell replication.
  • Dipyridamole and/or mirtazapine treatment promoted beta-cell replication in mice.
  • Dipyridamole treatment in humans was associated with reduced glucose levels.

Conclusions:

  • This study reveals novel mechanisms of cAMP-dependent beta-cell growth regulation.
  • Commonly prescribed medications like dipyridamole and mirtazapine show potential for influencing beta-cell mass and function.
  • These findings offer new therapeutic strategies for diabetes by targeting beta-cell regeneration.